Tilray Brands (TLRY) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Tilray Brands (TLRY) Net Income towards Common Stockholders Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Tilray Brands | 516.11 Mn | 281.48 Mn | 90.52 Mn | 96.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 96.73% |
| Feb 28, 2026 | 96.82% |
| Nov 30, 2025 | 48.98% |
| Aug 31, 2025 | 104.37% |
| May 31, 2025 | -9,797.92% |
| Feb 28, 2025 | -655.87% |
| Nov 30, 2024 | -84.65% |
| Aug 31, 2024 | 37.97% |
| May 31, 2024 | -94.74% |
| Feb 29, 2024 | 91.22% |
| Nov 30, 2023 | 45.71% |
| Aug 31, 2023 | 15.09% |
| May 31, 2023 | 147.75% |
| Feb 28, 2023 | -2,378.71% |
| Nov 30, 2022 | -1,567.33% |
| Aug 31, 2022 | -90.13% |
| May 31, 2022 | -238.27% |
| Feb 28, 2022 | 31.19% |
| Nov 30, 2021 | 106.50% |
| Aug 31, 2021 | -59.14% |